ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.

Eui-Soon Kim et al.PubMed ↗Publisher ↗

No numbers read from the abstract.